Brain tumor scans could use safer, lower contrast doses

NCT ID NCT04113395

Completed Diagnosis Sponsor: Fondation Ophtalmologique Adolphe de Rothschild Source: ClinicalTrials.gov ↗

First seen Jan 05, 2026 · Last updated May 22, 2026 · Updated 23 times

Summary

This study tested whether using a much lower dose of gadolinium contrast in MRI scans can still accurately detect meningiomas, a common type of brain tumor. Over 500 adults undergoing routine screening or follow-up for meningiomas received both a standard full-dose MRI and a new low-dose sequence. The goal is to reduce patients' lifetime exposure to gadolinium, which can build up in the body, while maintaining reliable tumor detection.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MENINGIOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

CHU de Bordeaux

Bordeaux, 33076, France
CHU de Grenoble

Grenoble, Grenoble, 38100, France
CHU de Limoges

Limoges, Limoges, 87042, France
CHU de Lyon

Lyon, Lyon, 69495, France
CHU de Nantes

Nantes, Nantes, 44800, France
CHU de Rennes

Rennes, Rennes, 35033, France
CHU de Rouen

Rouen, Rouen, 76000, France
CHU de Strasbourg

Strasbourg, Strasbourg, 67000, France
CHU de Tours

Tours, Tours, France
Fondation ophtalmique Adolphe de Rothschild

Paris, Paris, 75019, France

Conditions

Explore the condition pages connected to this study.

MENINGIOMA MENINGIOMA